Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories Limited (RDY) generates a steady flow of news across product launches, clinical collaborations, financial results and regulatory updates. As a global pharmaceutical company headquartered in Hyderabad, India and active in APIs, generics, branded generics, biosimilars and OTC products, its announcements span multiple therapeutic areas and regions.
News coverage for Dr. Reddy's often includes product and portfolio updates, such as the first-to-market U.S. launch of over-the-counter olopatadine hydrochloride ophthalmic solution USP, 0.7%, the generic equivalent of Extra Strength Pataday Once Daily Relief. The company also reports on new brands and in-licensed assets in India and Emerging Markets, including vaccines and allergy immunotherapy products.
Investors and industry followers will find regular earnings and financial disclosures, where Dr. Reddy's presents consolidated IFRS results, segment performance for Global Generics and Pharmaceutical Services and Active Ingredients, and commentary on regional trends in North America, Europe, India and Emerging Markets. These releases provide insight into pricing dynamics, product launches and contributions from acquisitions such as nicotine replacement therapy portfolios.
Another important stream of news relates to biosimilar and biotech partnerships. Dr. Reddy's announces collaborations with companies like Alvotech, Shanghai Henlius Biotech and Bio-Thera Solutions for biosimilar candidates targeting denosumab, daratumumab, ustekinumab and golimumab, among others. Updates from Aurigene Oncology, its wholly owned subsidiary, cover early clinical data and platform presentations in oncology.
Regulatory and safety communications also appear in the news feed, including recalls of specific product lots and summaries of inspection outcomes at manufacturing and API facilities. For readers tracking RDY, this page offers a consolidated view of these developments, making it easier to follow how the company’s strategy, pipeline and operations evolve over time.
Dr. Reddy’s Laboratories has launched Cinacalcet Tablets, a generic version of Sensipar, approved by the USFDA. This therapeutic equivalent is expected to capture a share of the Sensipar market, which reported U.S. sales of about $312 million in the last twelve months ending July 2020. The tablets are available in 30 mg, 60 mg, and 90 mg dosages, packaged in bottles of 30. This launch aims to provide affordable treatment options and enhance Dr. Reddy's competitive product portfolio in the pharmaceutical market.
Dr. Reddy's Laboratories has launched Dimethyl Fumarate Delayed-Release Capsules, a generic equivalent of Tecfidera®, approved by the U.S. FDA. The launch addresses a significant market, with U.S. sales of the Tecfidera® brand reaching approximately $3.8 billion for the twelve months ending June 2020, according to IQVIA Health. The new capsules are available in 120 mg and 240 mg strengths, offered in bottles of 14 and 60 capsules. This development expands Dr. Reddy's generics portfolio aimed at providing affordable medicines.